Abstract:Introduction High dose chemotherapy (HDC), such as carmustine/etoposide/cytarabine/melphalan (BEAM), followed by autologous stem cell transplantation (ASCT) was a standard of care for patients with relapsed/refractory and poor-risk lymphomas for over decades. However, with the introduction of new drugs, such as rituximab, patients relapsed from or refractory to first line therapy benefit less from HDC with ASCT. To improve the survival of these patients with ASCT, better HDC combination is urgently needed. Our previous research indicated the combination of cladribine/gemcitabine/busulfan (CGB) had strong synergistic effect against lymphoma cell lines. Adding Histone deacetylases inhibitor (HDACi), vorinostat or chidamide (chi), to CGB further enhanced cytotoxicity, which warrant the clinical use of ChiCGB combination as conditioning chemotherapy. We started a phase II clinical trial to evaluate the efficacy and safety of ChiCGB followed by ASCT in patients with relapsed/refractory and poor-risk lymphomas Patients and methods Eligibility included ages 18 to 65 and one of the following lymphomas: High-risk and relapsed/refractory (R/R) diffuse large B cell lymphomas (DLBCL), T and natural killer/T (NK/T) cell lymphoma, and hodgkin lymphoma (HL). Additional eligibility criteria included adequate renal, hepatic, pulmonary, cardiac function, performance status 0 to 1, no active hepatitis B or C. Patients received oral chidamide 30mg on days -7, -4, 0, +3. Cladribine was administered intravenously at the dose of 10 mg from days -6 to -2. Gemcitabine was administered intravenously 4 hours after the finish of cladribine at the dose of 2500 mg/m2 on days -6 and -2. Busulfan was administered intravenously at dose of 3.2 mg/kg on days -6 to -2. Dexamethasone 10 mg i.v. was given from day -6 to -2. Infusion of peripheral blood stem cells was on day 0. CR, OS and progression free survival(PFS) were calculated using standard methods. Statistical analysis was done using Fishers exact test or Chi-square test / Kruskal-Wallis test. Kaplan-Meier method was used for time-to-event analysis including overall survival and progression free survival. The Wilcoxon test was used to evaluate the difference in time-to-event endpoints between patient groups. Results Forty-three patients were enrolled between Apr. 2015 and Apr. 2017. Median age was 34 years (range, 22-62). The diagnoses were DLBCL (N=19), TN 2 had IVLBCL; 1 had transformed DLBCL; 13 had stage IV extranodal natural killer/T cell lymphoma (ENKTCL); and 2 had lymphoblastic T cell lymphoma. Twenty-tow patients were in first CR, 21 had R/R disease, and 5 had PET positive tumor before HDC. Stem cells source was peripheral blood. Median infused CD34+cells count was 2.1×106/Kg (range, 1.0 to 11.6×106/Kg). Neutrophils and platelets were engrafted on a median day +11 (range, days +8 to +14) and day +12 (range, days +9 to +22), respectively. The median follow-up is 10.3 months (range, 3-26.5 months). The progression free survival (PFS) and overall survival (OS) of the whole cohort are 78.2% and 89.5%, respectively (Figure-1A). The PFS and OS in DLBCL group are 81.7% and 100% respectively (Figure-1B). Of 19 patients with DLBCL, only 2 with IVLBCL relapsed at 5.7 and 11.1 months post transplantation respectively. The EFS and OS in TN P=0.039) (Figure-1D). The most common adverse event was infection. Thirty-nine (90.7%) patients developed grade 3 neutropenic fever. Other notable toxicities included grade 2 (55.8%) and 3 (9.3%) mucositis, grade 2 (13.9%) and 3 (4.7%) dermatitis, grade 2 (9.3%) diarrhea and self-limited transaminase elevation. All these toxicities were manageable and there was no therapy-related mortality. Conclusion Our study showed ChiCGB combination can be safely administered as HDC before ASCT for patients with R/R or high-risk lymphomas. This combination showed promising early outcomes and warrant further clinical investigations. Disclosures No relevant conflicts of interest to declare.

Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?

Long-Term Outcome of Gemcitabine, Vinorelbine, Liposomal-Doxorubicin (gvd) As Salvage Regimen for Patients with Previously Heavily Treated Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12

Chidamide, A Hdac Inhibitor, Combined With Cladribine, High Dose Gemcitabine And Busulfan With Autologous Stem Cell Transplantation In Patients With Relapsed/Refractory And Poor-Risk Lymphoma

A New Conditioning Regimen with Chidamide, Cladribine, Gemcitabine and Busulfan Significantly Improve the Outcome of High-Risk or Relapsed/refractory Non-Hodgkin's Lymphomas

Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy

High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors

Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy

Rituximab, Gemcitabine, Cisplatin, and Dexamethasone in Patients with Refractory or Relapsed Aggressive B-cell Lymphoma

Promising Long-Term Outcome of Gemcitabine, Vinorelbine, Liposomal Doxorubicin (GVD) in 14-Day Schedule As Salvage Regimen for Patients with Previously Heavily Treated Hodgkin’s Lymphoma and Aggressive Non-Hodgkin’s Lymphoma

Efficacy and Adverse Reactions of Gemcitabine Combined with Cyclophosphamide, Vinblastine and Prednisone Hydrogenation Regiments in Relapse And/or Refractory Non-Hodgkin's Lymphoma

High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom

High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas

[Outpatient reinduction therapy with gemcitabine, dexamethasone, Cisplatin (GDP) for patients with relapsed and refractory lymphoma]

Safety and Efficacy of GBC/GBM Conditioning Regimen Followed By Autologous Stem Cell Transplantation in Lymphoid Malignancies

A trial of gemcitabine (gems) in combination with cisplatin for treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)

P1090: CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL

Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with High-Risk Stage III to IV Hodgkin Lymphoma: a Multicenter Retrospective Cohort Study.

Role of Pegylated Liposomal Doxorubicin in Heavily Pretreated Relapsed Refractory Hodgkin Lymphoma Eligible for Autologous or Allogeneic Transplantation

Efifcacy of the consolidation chemotherapy after autologous stem cell transplantation in refractory/relapse lymphoma

Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma